Added Benefits and User Satisfaction with a Low-Dose Oral Contraceptive Containing Drospirenone

@article{Bitzer2009AddedBA,
  title={Added Benefits and User Satisfaction with a Low-Dose Oral Contraceptive Containing Drospirenone},
  author={Johannes Bitzer and Anna Maria Paoletti},
  journal={Clinical Drug Investigation},
  year={2009},
  volume={29},
  pages={73-78}
}
The ethinylestradiol 20 μg/drospirenone 3 mg combined oral contraceptive (COC), administered in cycles of 21 days continuous use followed by a 7-day hormone-free interval (21/7) [Yasminelle®], has been proven to be an effective and well tolerated contraceptive with an acceptable bleeding pattern and good safety profile. In addition, the ethinylestradiol 20 μg/drospirenone 3 mg 21/7 COC prevents water-retention-related weight gain, and improves physical and emotional well-being, consistent with… 

Psychosexual well-being in women using oral contraceptives containing drospirenone.

It seems likely that the use of a low-dose, well-balanced OC and the shorter 4-day hormone-free interval may minimize the side effects that can impair quality of life and thus increase women's compliance with hormonal contraception therapy.

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

The present study shows that 15 mg estetrol combined with 3”mg DRSP is associated with a high-user acceptability and satisfaction, and with a favourable body weight control.

Tailoring combination oral contraceptives to the individual woman.

Assisted counseling to raise awareness of the specific characteristics of the different COC options available may optimize adherence and patient acceptability and offer improvements over their predecessors.

Health Status Is Affected, and Phase I/II Biotransformation Activity Altered in Young Women Using Oral Contraceptives Containing Drospirenone/Ethinyl Estradiol

COCs containing DRSP/EE may, therefore, adversely affect health status and disturb the balance between phase I and II biotransformation reactions, which may be mediated by oxidative stress.

Evaluating the Cognitive Impacts of Drospirenone, a Spironolactone-Derived Progestin, Independently and in Combination With Ethinyl Estradiol in Ovariectomized Adult Rats

Drospirenone, a spironolactone-derived progestin, is investigated, which has unique pharmacological properties compared to other clinically-available progestins and natural progesterone, for its impact on spatial memory, anxiety-like behavior, and brain regions crucial to these cognitive tasks.

Индивидуальный выбор гормонального контрацептивного средства

The presented review substantiates the algorithm for the individual selection of a hormonal drug depending on the clinical portrait of a woman in order to solve the problem of reliable and safe protection from pregnancy with preventive and therapeutic effects.

Contraception in Perimenopausal Women

References

SHOWING 1-10 OF 31 REFERENCES

The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.

Clinical trials with EE/DRSP indicate that it is a well-tolerated combined oral contraceptive that has a positive effect on body weight, skin and the symptoms of premenstrual syndrome and appears to improve specific aspects associated with feelings of well-being, which may result in better compliance.

Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone

  • J. HuberJ. Foidart R. Heithecker
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
The combination of 30 g ethinylestradiol/3 mg drospirenone provides effective oral contraception, excellent cycle control, good tolerability and a level of weight loss that may have a significant beneficial effect on compliance in women with a tendency to weight gain due to water retention.

Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder

A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 &mgr;g improves symptoms associated with premenstrual dysphoric disorder.

A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.

The combination of 30 microg ethinylestradiol combined with 3 mg drospirenone provides effective oral contraception and good cycle control, and is well tolerated.

Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms

  • D. ApterA. Borsos S. Kelly
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2003
3 mg drospirenone in combination with 30 μg ethinylestradiol has been shown to have a beneficial effect on psychological general well-being, as measured by thePGWBI, the first study on oral contraceptives which has used the PGWBI in this population.

A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.

An oral contraceptive containing drospirenone/ethinyl estradiol may reduce the premenstrual symptoms of negative affect, water retention and increased appetite.

Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20μg and Drospirenone 3mg

The EE 20μg/drsp 3 mg combined oral contraceptive is an effective and well tolerated contraceptive with an acceptable bleeding pattern and was well tolerated and adverse events experienced were typical of hormonal contraceptive use.

A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).

This formulation provides contraceptive efficacy similar to higher-dose oral contraceptives, while maintaining a safety and common OC side effect profile that is consistent with prior years of reported use with levonorgestrel-containing products.